Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment

Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review

(2019) Bing Cao et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis

(2019) William Jacobson et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma

(2019) Michael Cronquist Christensen et al.   JOURNAL OF AFFECTIVE DISORDERS

Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD)

(2018) Pratap Chokka et al.   CNS SPECTRUMS

Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders

(2018) Michael Cronquist Christensen et al.   JOURNAL OF AFFECTIVE DISORDERS

Efficacy of vortioxetine on the physical symptoms of major depressive disorder

(2018) Michael Cronquist Christensen et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression

(2018) Joshua D. Rosenblat et al.   JOURNAL OF AFFECTIVE DISORDERS

Emotional blunting with antidepressant treatments: A survey among depressed patients

(2017) G.M. Goodwin et al.   JOURNAL OF AFFECTIVE DISORDERS

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder

(2017) Ioana Florea et al.   Brain and Behavior

The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials

(2016) RS McIntyre et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms

(2016) David S. Baldwin et al.   JOURNAL OF AFFECTIVE DISORDERS

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

(2016) Roger S. McIntyre et al.   JOURNAL OF CLINICAL PSYCHIATRY

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies

(2016) David S Baldwin et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Assessing anhedonia in depression: Potentials and pitfalls

(2016) Sakina J. Rizvi et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

The Effect of Vortioxetine on Health-related Quality of Life in Patients With Major Depressive Disorder

(2015) Ioana Florea et al.   CLINICAL THERAPEUTICS

Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters

(2015) Stephen M. Stahl   CNS SPECTRUMS

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

(2015) Atul R Mahableshwarkar et al.   NEUROPSYCHOPHARMACOLOGY

Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data

(2015) Connie Sanchez et al.   PHARMACOLOGY & THERAPEUTICS

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelat

(2014) Stuart A. Montgomery et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants

(2014) John Read et al.   PSYCHIATRY RESEARCH

Patient-centered assessment of cognitive symptoms of depression

(2013) Sheri E. Fehnel et al.   CNS SPECTRUMS

Serotonergic Drugs for Depression and Beyond

(2013) Stephen M. Stahl et al.   CURRENT DRUG TARGETS

Rational site-directed pharmacotherapy for major depressive disorder

(2013) Pierre Blier   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D)

(2013) Waguih William IsHak et al.   JOURNAL OF AFFECTIVE DISORDERS

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

(2012) Cornelius Katona et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

The Oxford Questionnaire on the Emotional Side-effects of Antidepressants (OQuESA): Development, validity, reliability and sensitivity to change

(2012) Jonathan Price et al.   JOURNAL OF AFFECTIVE DISORDERS

Fluoxetine (Prozac) and Serotonin Act on Excitatory Synaptic Transmission to Suppress Single Layer 2/3 Pyramidal Neuron-Triggered Cell Assemblies in the Human Prefrontal Cortex

(2012) G. Komlosi et al.   JOURNAL OF NEUROSCIENCE

Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms

(2011) R. Uher et al.   PSYCHOLOGICAL MEDICINE

Relevance of Norepinephrine-Dopamine Interactions in the Treatment of Major Depressive Disorder

(2010) Mostafa El Mansari et al.   CNS Neuroscience & Therapeutics

Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum

(2010) Charles H. K. West et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Reconsidering anhedonia in depression: Lessons from translational neuroscience

(2010) Michael T. Treadway et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study

(2009) Jonathan Price et al.   BRITISH JOURNAL OF PSYCHIATRY

Implications of the DSM's emphasis on sadness and anhedonia in major depressive disorder

(2008) Julia D. Buckner et al.   PSYCHIATRY RESEARCH